Biohazard2020/2021-COVID-19 novel coronavirus (2019-nCoV))病毒: 新型冠状病毒 2019-nCoV

Moorestown, New Jersey, United States

7322321334

7322321334

  • biotecMAX
    • BioHazard2020-3
    • BioHazard2020-2
    • BioHazard2020-1
    • BioHazard2020-0
    • 2021-1
    • 2020-6
    • 2020-5
    • 2020-4
    • 2020-3
    • 2020-2
    • 2020-1
    • 2019-12
    • 2019-11
    • 2019-10
    • 2019-9
    • 2019-8
    • 2019-7
    • 2019-4
    • 2019-3
    • biotecNOVA 2
    • BiotecNOVA 1
    • biotecHOPE
    • biotecHEART
    • portfolio
    • BiotecDATA
    • biotechVORTEX 2
    • biotechVORTEX 1
    • biotechSTORM/BiotecWARS
    • blogs
    • about
    • biotecMAX
    • BioHazard2021
      • BioHazard2020-3
      • BioHazard2020-2
      • BioHazard2020-1
      • BioHazard2020-0
    • BiotecMAX2021
      • 2021-1
    • biotecMAX2020
      • 2020-6
      • 2020-5
      • 2020-4
      • 2020-3
      • 2020-2
      • 2020-1
    • BiotecMAX2019
      • 2019-12
      • 2019-11
      • 2019-10
      • 2019-9
      • 2019-8
      • 2019-7
      • 2019-4
      • 2019-3
    • biotecNOVA
      • biotecNOVA 2
      • BiotecNOVA 1
    • BiotecHOPE
      • biotecHOPE
      • biotecHEART
    • biotecAlpha
      • portfolio
      • BiotecDATA
    • BiotechVortex
      • biotechVORTEX 2
      • biotechVORTEX 1
    • BiotecWARS
      • biotechSTORM/BiotecWARS
    • seeking biotech alpha
      • blogs
      • about
  • biotecMAX
seeking biotech alpha

seeking biotech alpha is biotecMAX 生物技术最大 1/24/2021 the heart of biotech

seeking biotech alpha is biotecMAX 生物技术最大 1/24/2021 the heart of biotechseeking biotech alpha is biotecMAX 生物技术最大 1/24/2021 the heart of biotech

BiotecDATA™

image688

welcome to BiotecDATA™

  

BiotecDATA™ is where we make cents and sense out of the data

image689

 

The top selling prescription drugs by revenue


  

Three Malls in Three States: A Weekend Shopping Trip Under Coronavirus

Americans in Ohio, Texas and Georgia are eager to get out of their homes; a patchwork of mask rules and nervous retail workers

By Sarah Nassauer  in Toledo, Ohio; Cameron McWhirter  in Atlanta 

and Elizabeth Findell  in Houston

May 18, 2020 5:30 am ET 

 https://www.wsj.com/articles/three-malls-in-three-states-a-weekend-shopping-trip-under-coronavirus-11589794200?mod=hp_lead_pos5 

Coronavirus: A timeline of how the deadly COVID-19 outbreak is evolving
image690

Small-Business Loan Deadline Poses Test for Mnuchin

 

Small-Business Loan Deadline Poses Test for Mnuchin

The Treasury Secretary has given big companies until May 14 to return their Paycheck Protection Program loans or face criminal liability. Many borrowers are rebuffing those demands.

 

Coronavirus Live Updates: Full Economic Recovery May Await Vaccine, Fed Chairman Says

Seeking to encourage testing, Gov. Andrew M. Cuomo of New York has a nasal swab on live television.

President Trump, calling in to a charity golf exhibition, says he misses sports and wants “big, big stadiums loaded with people.”

 https://www.nytimes.com/2020/05/17/us/coronavirus-cases-deaths.html 


image691

iShares Nasdaq Biotechnology ETF

 

iShares Nasdaq Biotechnology ETF

  https://www.blackrock.com/us/individual/products/239699/ 


INVESTMENT OBJECTIVE

The iShares Nasdaq Biotechnology ETF seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. 

 
 as of Aug 26, 2020                     % of Market Value                                        

Biotechnology                                         78.60

Life Sciences Tools & Services           9.84

Pharmaceuticals                                       9.11

Health Care Equipment                         1.06

Health Care Services                               0.98

Cash and/or Derivatives                        0.14

Health Care Supplies                               0.11

Health Care Distributors                       0.09

Specialty Chemicals                                0.07


 https://seekingalpha.com/symbol/IBB 



 

iShares U.S. Pharmaceuticals ETF

 https://www.blackrock.com/us/individual/products/239519/ 

 

INVESTMENT OBJECTIVE

The iShares U.S. Pharmaceuticals ETF seeks to track the investment results of an index composed of U.S. equities in the pharmaceuticals sector. 


 as of Aug 26, 2020       % of Market Value

Pharmaceuticals              96.44

Biotechnology                     3.24

Cash and/or Derivatives  0.32 


 https://seekingalpha.com/symbol/IHE 



iShares U.S. Pharmaceuticals ETF
image692

 Economics

Jefferson County Bankruptcy Foreshadows Fate of Cities in Crisis

By Martin Z BraunMay 13, 2020, 9:06 AM EDT

  • After revenue loss, Alabama county cut back then went bankrupt
  • States, cities facing big budget gaps as jobs, taxes disappear

image693

 

API Sourcing: The Supply Side for US-Marketed Drugs

By Patricia Van Arnum - DCAT Editorial Director

November 20, 2019


 Brian Chappatta

Americans Have No Clue What's Next on Inflation

 https://www.bloomberg.com/opinion/articles/2020-05-17/coronavirus-economy-jumbles-inflation-expectations-in-the-u-s?srnd=premium 

image694

SPDR Select Sector Fund - Health Care (XLV)

 

SPDR Select Sector Fund - Health Care (XLV)

 

HOLDINGS AND WEIGHTINGS as of  as of 7:00 AM ET 01/22/2021  . Holdings and weightings are subject to change.

https://www.sectorspdr.com/sectorspdr/sector/xlv/portfolio


JNJ     JOHNSON + JOHNSON COMMON STOCK USD1.0                 9.60%

UNH   UNITEDHEALTH GROUP INC COMMON STOCK USD.01       7.59%

PFE     PFIZER INC COMMON STOCK USD.05                                         4.57%

MRK    MERCK + CO. INC. COMMON STOCK USD.5                              4.63%

ABT     ABBOTT LABORATORIES COMMON STOCK                              4.51%

ABBV   ABBVIE INC COMMON STOCK USD.01                                        4.43%

TMO    THERMO FISHER SCIENTIFIC INC COMMON STOCK             4.58%

 LLY      ELI LILLY + CO COMMON STOCK                                                    3.62%  

MDT     MEDTRONIC PLC COMMON STOCK USD.1                                3.58%

DHR     DANAHER CORP COMMON STOCK USD.01                               3.32%
AMGN  AMGEN INC COMMON STOCK USD.0001                                   3.31% 

BMY     BRISTOL MYERS SQUIBB CO COMMON STOCK USD .1         3.27%

 GILD   GILEAD SCIENCES INC COMMON STOCK USD.001                 1.89%
 

https://www.sectorspdr.com/sectorspdr/sector/xlv/performance

 

HEALTH CARE as of 3:43 PM ET 09/10/2020  XLV 


 Estimate Weight of XLV Components in the S&P 500 as of 09/09/2020 


https://www.nasdaq.com/market-activity/funds-and-etfs/xlv/dividend-history

image695

Barron's

 

ETFS

Want to Use ETFs to Play Biotech? Choose Wisely.

By Evie Liu Jan. 14, 2021 12:27 pm ET 

 

RELATED MARKET DATA

Funds & ETFs

 

Biotech ETFs: More diversified funds reduce risk – Barron’s

Jan. 16, 2021 8:14 PM ET ARK Genomic Revolution Multi-Sector ETF (ARKG)

By: Dulan Lokuwithana, SA News Editor 19 Comments

  • Given the difficulty in stock picking in the biotech space, the investors are better off with more diversified ETFs focused on the industry, according to an article in the latest issue of Barron’s.

https://seekingalpha.com/news/3652041-biotech-etfs-diversified-funds-reduce-risk-barron-s


image696

UK restricts parallel export of nearly 200 drugs

 

Covid-19: UK restricts parallel export of nearly 200 drugs, threatening its biopharma industry

By GlobalData Healthcare 

 13 MAY 2020 

image697

Fidelity® Select Pharmaceuticals Portfolio

 

Fidelity® Select Pharmaceuticals Portfolio

https://fundresearch.fidelity.com/mutual-funds/composition/316390442

 

Fidelity Select Pharmaceuticals (FPHAX)

https://www.nasdaq.com/market-activity/funds-and-etfs/fphax



 

Fidelity® Select Biotechnology Portfolio

https://fundresearch.fidelity.com/mutual-funds/composition/316390772

 

Fidelity Select Biotechnology Pt (FBIOX)

https://www.nasdaq.com/market-activity/funds-and-etfs/fbiox



 

Fidelity® Select Health Care Portfolio

https://fundresearch.fidelity.com/mutual-funds/composition/316390301

 

Fidelity Select Health Care (FSPHX)

https://www.nasdaq.com/market-activity/funds-and-etfs/fsphx



38th Annual J.P. Morgan Healthcare Conference Slideshows

ACADIA Pharmaceuticals Inc. (ACAD)

ACADIA Pharmaceuticals Inc. (ACAD)

ACADIA Pharmaceuticals Inc. (ACAD)

image698

  

ACADIA Pharmaceuticals (ACAD) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow

Jan. 15, 2020 6:06 PM ET|3 comments | About: ACADIA Pharmaceuticals Inc. (ACAD) ) 

Amgen Inc. (AMGN)

ACADIA Pharmaceuticals Inc. (ACAD)

ACADIA Pharmaceuticals Inc. (ACAD)

image699

 

Amgen (AMGN) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow

Jan. 15, 2020 6:13 PM ET | About: Amgen Inc. (AMGN) 

EXACT Sciences Corporation (EXAS)

ACADIA Pharmaceuticals Inc. (ACAD)

EXACT Sciences Corporation (EXAS)

image700

  

Exact Sciences (EXAS) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow

Jan. 16, 2020 1:51 PM ET  | About: Exact Sciences Corporation (EXAS) 



Moderna, Inc. (MRNA)

Alexion Pharmaceuticals, Inc. (ALXN)

EXACT Sciences Corporation (EXAS)

image701

 

Moderna (MRNA) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow

Jan. 15, 2020 3:27 PM ET|3 comments  | About: Moderna, Inc. (MRNA) 

Alexion Pharmaceuticals, Inc. (ALXN)

Alexion Pharmaceuticals, Inc. (ALXN)

Alexion Pharmaceuticals, Inc. (ALXN)

image702

 

Alexion Pharmaceuticals (ALXN) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow

Jan. 15, 2020 3:27 PM ET | About: Alexion Pharmaceuticals, Inc. (ALXN) 

Insulet Corporation (PODD)

Alexion Pharmaceuticals, Inc. (ALXN)

Alexion Pharmaceuticals, Inc. (ALXN)

image703

 

Insulet Corporation (PODD) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow

Jan. 15, 2020 1:45 PM ET | About: Insulet Corporation (PODD) 

38th Annual J.P. Morgan Healthcare Conference Slideshows

Amarin Corporation plc (AMRN)

BriaCell Therapeutics Corp. (BCTXF)

BriaCell Therapeutics Corp. (BCTXF)

 

Amarin (AMRN) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow

Jan. 17, 2020 9:31 AM ET | About: Amarin Corporation plc (AMRN) 

Amarin Plc (AMRN) Investor Presentation - Slideshow Mar. 3, 2020 8:19 AM ET|1 comment | About: Amarin Corporation plc (AMRN)

BriaCell Therapeutics Corp. (BCTXF)

BriaCell Therapeutics Corp. (BCTXF)

BriaCell Therapeutics Corp. (BCTXF)

image704

 

BriaCell Therapeutics (BCTXF) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow

Jan. 16, 2020 3:11 PM ET | About: BriaCell Therapeutics Corp. (BCTXF) 

Editas Medicine, Inc. (EDIT)

BriaCell Therapeutics Corp. (BCTXF)

Stemline Therapeutics, Inc. (STML)

image705

 

Editas Medicine (EDIT) Investor Presentation - Slideshow

Jan. 16, 2020 2:00 PM ET  | About: Editas Medicine, Inc. (EDIT)
 

Stemline Therapeutics, Inc. (STML)

Stemline Therapeutics, Inc. (STML)

Stemline Therapeutics, Inc. (STML)

image706

 

Stemline Therapeutics (STML) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow

Jan. 16, 2020 1:59 PM ET  | About: Stemline Therapeutics, Inc. (STML) 

BeiGene, Ltd. (BGNE)

Stemline Therapeutics, Inc. (STML)

Agilent Technologies, Inc. (A)

 

Beigene (BGNE) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow

Jan. 16, 2020 1:53 PM ET | About: BeiGene, Ltd. (BGNE) 

Beigene (BGNE) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow Jan. 16, 2020 1:53 PM ET|4 comments | About: BeiGene, Ltd. (BGNE)

Agilent Technologies, Inc. (A)

Stemline Therapeutics, Inc. (STML)

Agilent Technologies, Inc. (A)

image707

 

Agilent Technologies (A) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow

Jan. 15, 2020 6:10 PM ET | About: Agilent Technologies, Inc. (A) 

37th Annual J.P. Morgan Healthcare Conference Slideshows

CVS Health Corporation (CVS)

Karuna Therapeutics, Inc. (KRTX)

CVS Health Corporation (CVS)

image708

 

CVS Health Corporation (CVS) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow

Jan. 15, 2020 12:57 PM ET|7 comments | About: CVS Health Corporation (CVS) 

ImmunoGen, Inc. (IMGN)

Karuna Therapeutics, Inc. (KRTX)

CVS Health Corporation (CVS)

image709

 

ImmunoGen (IMGN) Investor Presentation - Slideshow

Jan. 16, 2020 1:30 PM ET | About: ImmunoGen, Inc. (IMGN) 

Karuna Therapeutics, Inc. (KRTX)

Karuna Therapeutics, Inc. (KRTX)

Karuna Therapeutics, Inc. (KRTX)

image710

 

Karuna Therapeutics (KRTX) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow

Jan. 17, 2020 11:16 AM ET | About: Karuna Therapeutics, Inc. (KRTX) 

ABIOMED, Inc. (ABMD)

Boston Scientific Corporation (BSX)

Karuna Therapeutics, Inc. (KRTX)

image711

 

Abiomed (ABMD) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow

Jan. 17, 2020 11:07 AM ET | About: Abiomed, Inc. (ABMD) 

Boston Scientific Corporation (BSX)

Boston Scientific Corporation (BSX)

Boston Scientific Corporation (BSX)

image712

 

Boston Scientific (BSX) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow

Jan. 15, 2020 6:05 PM ET  | About: Boston Scientific Corporation (BSX)  

Becton, Dickinson and Company (BDX)

Boston Scientific Corporation (BSX)

Boston Scientific Corporation (BSX)

image713

 

Becton Dickinson (BDX) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow

Jan. 15, 2020 6:09 PM ET  | About: Becton, Dickinson and Company (BDX) 

image714

Mapped: The World’s Top 10 Cities in 2035

Published 2 days ago on October 18, 2019By Iman Ghosh

 

Mapped: Where Will The Top 10 Cities Be in 2035?


 

Top 10 Cities by Projected GDP


 

Top 10 Cities by Future Population

 

 

Top 10 Cities By Estimated Annual GDP Growth


 https://www.visualcapitalist.com/top-10-cities/ 

Mapped: The World’s Top 10 Cities in 2035Published 2 days ago on October 18, 2019By Iman Ghosh

 

Mapped: The World’s Top 10 Cities in 2035

Published 2 days ago on October 18, 2019

By

Iman Ghosh
 

https://www.visualcapitalist.com/top-10-cities/ 


 

Weighing The Week Ahead: Earnings Season Opportunities

Oct. 20, 2019 6:55 AM ET|28 comments  | Includes: BAPR, BAUG, BIBL, BJUL, BJUN, BOCT, CHGX, CRF, DDM, DIA, DMRL, DOG, DUSA, DXD, EDOW, EEH, EPS, EQL, EQWL, ESGL, FEX, FWDD, GSEW, HUSV, IVV, IWL, IWM, JHML, JKD, OMFS, OTPIX, PAPR, PAUG, PJAN, PJUN, PMOM, PPLC, PSQ, QID, QLD, QQEW, QQQ, QQQE, QQXT, RSP, RVRS, RWL, RWM, RWSL, RYARX, RYRSX, SCAP, SCHX, SDOW, SDS, SFLA, SFY, SH, SMLL, SPDN, SPLX, SPSM, SPUU, SPXE, SPXL, SPXN, SPXS, SPXT, SPXU, SPXV, SPY, SQQQ, SRTY, SSO, SSPY, SYE, TNA, TQQQ, TRND, TWM, TZA, UAUG, UDOW, UDPIX, UJAN, UOCT, UPRO, URTY, USA, USMC, UWM, VFINX, VOO, VTWO, VV, ZFJeff MillerJeff MillerValue, Growth 


 https://seekingalpha.com/article/4297479-weighing-week-ahead-earnings-season-opportunities 

Weighing The Week Ahead: Earnings Season Opportunities Oct. 20, 2019 6:55 AM ET Jeff Miller Value, Growth

2019 Q3 - Results

Intercept Pharmaceuticals, Inc. (ICPT)

Intercept Pharmaceuticals, Inc. (ICPT)

Intercept Pharmaceuticals, Inc. (ICPT)

image715

 

Intercept Pharmaceuticals, Inc. 2019 Q3 - Results - Earnings Call Presentation

Nov. 5, 2019 11:26 AM ET | About: Intercept Pharmaceuticals, Inc. (ICPT) 

Neurocrine Biosciences, Inc. (NBIX)

Intercept Pharmaceuticals, Inc. (ICPT)

Intercept Pharmaceuticals, Inc. (ICPT)

image716

 

Neurocrine Biosciences, Inc. 2019 Q3 - Results - Earnings Call Presentation

Nov. 5, 2019 7:48 AM ET | About: Neurocrine Biosciences, Inc. (NBIX) 

: Amarin Corporation plc (AMRN)

Intercept Pharmaceuticals, Inc. (ICPT)

Becton, Dickinson and Company (BDX)

image717

 

Amarin Corporation plc 2019 Q3 - Results - Earnings Call Presentation

Nov. 5, 2019 3:32 PM ET  | About: Amarin Corporation plc (AMRN) 

Becton, Dickinson and Company (BDX)

Becton, Dickinson and Company (BDX)

Becton, Dickinson and Company (BDX)

image718

 

Becton, Dickinson and Company 2019 Q4 - Results - Earnings Call Presentation

Nov. 5, 2019 3:32 PM ET|1 comment | About: Becton, Dickinson and Company (BDX) 

QIAGEN N.V. (QGEN)

Becton, Dickinson and Company (BDX)

IN.PACT™ Admiral™ DCB

image719

 

QIAGEN N.V. 2019 Q3 - Results - Earnings Call Presentation

Nov. 5, 2019 2:28 PM ET | About: QIAGEN N.V. (QGEN) 

IN.PACT™ Admiral™ DCB

Becton, Dickinson and Company (BDX)

IN.PACT™ Admiral™ DCB

image720

 

Four-Year Data from the IN.PACT Global Study Highlight Durable Performance and Safety of IN.PACT™ Admiral™ DCB

Tue November 5, 2019 1:15 PM|GlobeNewswire|About: MDT

Longest-Term Data from a Real-World PAD Patient Population Presented at VIVA

DUBLIN and LAS VEGAS, Nov. 05, 2019 (GLOBE NEWSWIRE) --  Medtronic plc (MDT)

DCB TECHNOLOGY IN.PACT Admiral Drug-Coated Balloon

2019 Q3 - Results

Celgene Corporation (CELG)

Celgene Corporation (CELG)

Celgene Corporation (CELG)

image721

 

Celgene Corporation 2019 Q3 - Results - Earnings Call Presentation

Nov. 1, 2019 11:58 AM ET|5 comments | About: Celgene Corporation (CELG) 

Exelixis, Inc. (EXEL)

Celgene Corporation (CELG)

Celgene Corporation (CELG)

image722

 

Exelixis, Inc. 2019 Q3 - Results - Earnings Call Presentation

Oct. 31, 2019 3:51 PM ET|1 comment | About: Exelixis, Inc. (EXEL) 

Sanofi (SNY)

Celgene Corporation (CELG)

bluebird bio, Inc. (BLUE)

image723

 

Sanofi 2019 Q3 - Results - Earnings Call Presentation

Oct. 31, 2019 1:57 PM ET | About: Sanofi (SNY) 

bluebird bio, Inc. (BLUE)

Vertex Pharmaceuticals Incorporated (VRTX)

bluebird bio, Inc. (BLUE)

 

bluebird bio (BLUE) Investor Presentation - Slideshow

Nov. 2, 2019 2:03 PM ET|1 comment | About: bluebird bio, Inc. (BLUE) 

bluebird bio (BLUE) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow Feb. 20, 2020 7:12 AM ET|1 comment | About: bluebird bio, Inc. (BLUE)

GlaxoSmithKline plc (GSK)

Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Incorporated (VRTX)

image724

 

GlaxoSmithKline plc 2019 Q3 - Results - Earnings Call Presentation

Oct. 30, 2019 10:13 AM ET | About: GlaxoSmithKline plc (GSK) 

Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Incorporated (VRTX)

image725

 

Vertex Pharmaceuticals Incorporated 2019 Q3 - Results - Earnings Call Presentation

Nov. 3, 2019 10:53 PM ET | About: Vertex Pharmaceuticals Incorporated (VRTX) 

2019 Q3 - Results

Merck & Co., Inc. (MRK)

Incyte Corporation (INCY)

Merck & Co., Inc. (MRK)

image726

 

Merck & Co., Inc. 2019 Q3 - Results - Earnings Call Presentation

Oct. 29, 2019 8:34 AM ET | About: Merck & Co., Inc. (MRK) 



Pfizer Inc. (PFE)

Incyte Corporation (INCY)

Merck & Co., Inc. (MRK)

image727

 

Pfizer Inc. 2019 Q3 - Results - Earnings Call Presentation

Oct. 29, 2019 7:26 AM ET  | About: Pfizer Inc. (PFE) 



Incyte Corporation (INCY)

Incyte Corporation (INCY)

Incyte Corporation (INCY)

 

Incyte Corporation 2019 Q3 - Results - Earnings Call Presentation

Oct. 29, 2019 9:32 AM ET | About: Incyte Corporation (INCY) 



Amgen Inc. (AMGN)

Seattle Genetics, Inc. (SGEN)

Incyte Corporation (INCY)

image728

 

Amgen Inc. 2019 Q3 - Results - Earnings Call Presentation

Oct. 29, 2019 4:59 PM ET | About: Amgen Inc. (AMGN) 

NovoCure Limited (NVCR)

Seattle Genetics, Inc. (SGEN)

Seattle Genetics, Inc. (SGEN)

image729

. 

NovoCure Limited 2019 Q3 - Results - Earnings Call Presentation

Oct. 31, 2019 12:28 PM ET  | About: NovoCure Limited (NVCR) 

Seattle Genetics, Inc. (SGEN)

Seattle Genetics, Inc. (SGEN)

Seattle Genetics, Inc. (SGEN)

image730

 

Seattle Genetics, Inc. 2019 Q3 - Results - Earnings Call Presentation

Oct. 29, 2019 8:04 PM ET | About: Seattle Genetics, Inc. (SGEN) 

2019 Q3 - Results

Thermo Fisher Scientific Inc. (TMO)

Thermo Fisher Scientific Inc. (TMO)

Thermo Fisher Scientific Inc. (TMO)

image731

 

Thermo Fisher Scientific Inc. 2019 Q3 - Results - Earnings Call Presentation

Oct. 23, 2019 9:57 AM ET | About: Thermo Fisher Scientific Inc. (TMO) 

Novartis AG (NVS)

Thermo Fisher Scientific Inc. (TMO)

Thermo Fisher Scientific Inc. (TMO)

image732

 

Novartis AG 2019 Q3 - Results - Earnings Call Presentation

Oct. 22, 2019 6:53 AM ET | About: Novartis AG (NVS) 

Amarin Corporation plc (AMRN)

Thermo Fisher Scientific Inc. (TMO)

Amarin Corporation plc (AMRN)

image733

 

Amarin Corporation (AMRN) Investor Presentation - Slideshow

Oct. 3, 2019 10:59 AM ET|11 comments  | About: Amarin Corporation plc (AMRN) 

AstraZeneca PLC (AZN)

Gilead Sciences, Inc. (GILD)

Amarin Corporation plc (AMRN)

image734

 

AstraZeneca PLC 2019 Q3 - Results - Earnings Call Presentation

Oct. 24, 2019 10:19 AM ET | About: AstraZeneca PLC (AZN) 



AstraZeneca PLC 2020 Q1 - Results - Earnings Call Presentation Apr. 29, 2020 8:29 AM ET | About: AstraZeneca PLC (AZN), AZNCF

Gilead Sciences, Inc. (GILD)

Gilead Sciences, Inc. (GILD)

Gilead Sciences, Inc. (GILD)

image735

 

Gilead Sciences, Inc. 2019 Q3 - Results - Earnings Call Presentation

Oct. 24, 2019 4:31 PM ET|1 comment  | About: Gilead Sciences, Inc. (GILD) 

Illumina, Inc. (ILMN)

Gilead Sciences, Inc. (GILD)

Gilead Sciences, Inc. (GILD)

image736

 

Illumina, Inc. 2019 Q3 - Results - Earnings Call Presentation

Oct. 24, 2019 6:25 PM ET|2 comments | About: Illumina, Inc. (ILMN) 

2019 Q3 - Results

Boston Scientific Corporation (BSX)

About: Alexion Pharmaceuticals, Inc. (ALXN)

Boston Scientific Corporation (BSX)

image737

 

Boston Scientific Corporation 2019 Q3 - Results - Earnings Call Presentation

Oct. 23, 2019 8:21 AM ET | About: Boston Scientific Corporation (BSX) 

Alkermes plc (ALKS)

About: Alexion Pharmaceuticals, Inc. (ALXN)

Boston Scientific Corporation (BSX)

image738

 

Alkermes plc 2019 Q3 - Results - Earnings Call Presentation

Oct. 23, 2019 7:57 AM ET | About: Alkermes plc (ALKS) 

About: Alexion Pharmaceuticals, Inc. (ALXN)

About: Alexion Pharmaceuticals, Inc. (ALXN)

About: Alexion Pharmaceuticals, Inc. (ALXN)

image739

 

Alexion Pharmaceuticals, Inc. 2019 Q3 - Results - Earnings Call Presentation

Oct. 23, 2019 9:59 AM ET | About: Alexion Pharmaceuticals, Inc. (ALXN) 

Veracyte, Inc. (VCYT)

Eli Lilly and Company (LLY)

About: Alexion Pharmaceuticals, Inc. (ALXN)

image740

 

Veracyte, Inc. 2019 Q3 - Results - Earnings Call Presentation

Oct. 23, 2019 12:37 AM ET | About: Veracyte, Inc. (VCYT) 

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)

image741

  

Eli Lilly and Company 2019 Q4 - Results - Earnings Call Presentation

Jan. 30, 2020 10:25 AM ET | About: Eli Lilly and Company (LLY) 


Biogen Inc. (BIIB)

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)

image742

 

Biogen Inc. 2019 Q4 - Results - Earnings Call Presentation

Jan. 30, 2020 7:56 AM ET|1 comment | About: Biogen Inc. (BIIB)  

BAC Global HealthCare Conference & ESMO Congress 2019

Incyte Corporation (INCY)

Incyte Corporation (INCY)

Incyte Corporation (INCY)

image743

 

Incyte Corporation (INCY) Presents At Bank of America Merrill Lynch Global Healthcare Conference - Slideshow

Sep. 19, 2019 10:11 AM ET | About: Incyte Corporation (INCY) 

About: Amgen Inc. (AMGN)

Incyte Corporation (INCY)

Incyte Corporation (INCY)

image744

 

Amgen Inc. (AMGN) Management Presents at The Bank of America Merrill Lynch Global Healthcare Conference (Transcript)

Sep. 18, 2019 9:01 AM ET | About: Amgen Inc. (AMGN) 

Amgen To Present At The Bank of America Merrill Lynch Global Healthcare Conference THOUSAND OAKS, Calif., Sept. 13, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN)

Amgen Inc. (AMGN)

Incyte Corporation (INCY)

: Novartis AG (NVS)

image745

 

Amgen (AMGN) Presents At ESMO Congress 2019 - Slideshow

Oct. 2, 2019 12:20 PM ET | About: Amgen Inc. (AMGN) 

: Novartis AG (NVS)

Bristol-Myers Squibb Company (BMY)

: Novartis AG (NVS)

image746

 

Novartis AG (NVS) Updates on Kisqali® MONALEESA-3 ESMO Data - Slideshow

Oct. 1, 2019 1:15 PM ET | About: Novartis AG (NVS) 

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)

image747

. 

Bristol-Myers Squibb (BMY) Presents At ESMO Congress 2019 - Slideshow

Sep. 30, 2019 3:34 PM ET | About: Bristol-Myers Squibb Company (BMY) 

AstraZeneca PLC (AZN)

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)

image748

 

AstraZeneca Group (AZN) Presents At ESMO Congress 2019 - Slideshow

Oct. 2, 2019 12:06 PM ET | About: AstraZeneca PLC (AZN) 

Wainwright 21st Annual Global Investment Conference

CytoDyn (CYDY)

GW Pharmaceuticals plc (GWPH)

Sesen Bio, Inc. (SESN)

image749

 

CytoDyn (CYDY) Investor Presentation - Slideshow

Sep. 16, 2019 12:51 PM ET | About: CytoDyn Inc. (CYDY) 

Pipeline

Sesen Bio, Inc. (SESN)

GW Pharmaceuticals plc (GWPH)

Sesen Bio, Inc. (SESN)

image750

 

Sesen Bio (SESN) Presents At H.C. Wainwright 21st Annual Global Investment Conference - Slideshow

Sep. 16, 2019 1:51 PM ET | About: Sesen Bio, Inc. (SESN) 

we are developing fusion protein therapeutics for the treatment of cancer.

GW Pharmaceuticals plc (GWPH)

GW Pharmaceuticals plc (GWPH)

ProBeam 360 Proton Therapy System

image751

 

GW Pharmaceuticals (GWPH) Investor Presentation - Slideshow

Sep. 16, 2019 1:53 PM ET | About: GW Pharmaceuticals plc (GWPH) 

GW is the global leader in developing cannabinoid-based medicines.

ProBeam 360 Proton Therapy System

Phase I/IIa clinical trial of Bria-IMT™, BriaCell’s lead candidate, with pembrolizumab [KEYTRUDA®;

ProBeam 360 Proton Therapy System

image752

 

Varian Announces Multi-room Configuration for ProBeam 360 Proton Therapy System

Mon September 16, 2019 8:00 AM|PR Newswire|About: VAR

PALO ALTO, Calif., Sept. 16, 2019 /PRNewswire/ -- Varian (VSEA) (NYSE: VAR)

The ProBeam® 360° Proton Therapy System is designed for next-generation proton therapy, offering uncompromised clinical capabilities with ultra-high dose rates, a 360-degree gantry, and exceptional precision, all within a 30% smaller footprint.

Phase I/IIa clinical trial of Bria-IMT™, BriaCell’s lead candidate, with pembrolizumab [KEYTRUDA®;

Phase I/IIa clinical trial of Bria-IMT™, BriaCell’s lead candidate, with pembrolizumab [KEYTRUDA®;

Phase I/IIa clinical trial of Bria-IMT™, BriaCell’s lead candidate, with pembrolizumab [KEYTRUDA®;

image753

 

BriaCell to Present September 19th at 2nd Annual Next Gen Immuno-Oncology Congress in Philadelphia

Mon September 16, 2019 6:30 AM|GlobeNewswire|About: BCTXF, INCY, MRK

BERKELEY, Calif., Sept. 16, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (BCTXF) ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF)

BriaCell to Present September 19th at 2nd Annual Next Gen Immuno-Oncology Congress in Philadelphia POSTED ON SEPTEMBER 16, 2019 BY FARRAH DEAN BERKELEY, Calif., and VANCOUVER, British Columbia, September 16, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF),

VCF Care Pathway

Phase I/IIa clinical trial of Bria-IMT™, BriaCell’s lead candidate, with pembrolizumab [KEYTRUDA®;

Phase I/IIa clinical trial of Bria-IMT™, BriaCell’s lead candidate, with pembrolizumab [KEYTRUDA®;

image754

 

National Osteoporosis Foundation Supports New Evidence-Based Care Pathway Designed to Optimize Care for Vertebral Compression Fractures (VCF)

Mon September 16, 2019 10:00 AM|GlobeNewswire|About: MDTGlobeNewswire

DUBLIN, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (MDT)

A Clinical Care Pathway Developed by a Multispecialty Panel Using the RAND™/UCLA Appropriateness Method

earnings Call Slides Q2./HY 2019

EPS of $0.60495522880967928366 beats by $0.01 Revenue of $4.51B (5.61% Y/Y) beats by $84.19M

EPS of $0.60495522880967928366 beats by $0.01 Revenue of $4.51B (5.61% Y/Y) beats by $84.19M

EPS of $0.60495522880967928366 beats by $0.01 Revenue of $4.51B (5.61% Y/Y) beats by $84.19M

image755

 

Novo Nordisk A/S 2019 Q2 - Results - Earnings Call Slides

Aug. 14, 2019 3:43 PM ET | About: Novo Nordisk A/S (NVO) 

Insulet Corporation (PODD)

EPS of $0.60495522880967928366 beats by $0.01 Revenue of $4.51B (5.61% Y/Y) beats by $84.19M

EPS of $0.60495522880967928366 beats by $0.01 Revenue of $4.51B (5.61% Y/Y) beats by $84.19M

image756

 

Insulet (PODD) Presents At Canaccord Genuity Growth Conference - Slideshow

Aug. 13, 2019 2:31 PM ET | About: Insulet Corporation (PODD) 

China Biologic Products Holdings, Inc. (CBPO)

EPS of $0.60495522880967928366 beats by $0.01 Revenue of $4.51B (5.61% Y/Y) beats by $84.19M

China Biologic Products Holdings, Inc. (CBPO)

image757

 

China Biologic Products Holdings, Inc. 2019 Q2 - Results - Earnings Call Slides

Aug. 7, 2019 12:12 PM ET | About: China Biologic Products Holdings, Inc. (CBPO) .

CRISPR Therapeutics AG (CRSP)

EPS of $-0.26 beats by $0.09 Revenue of $17.55M (-18.06% Y/Y) beats by $3.96M

China Biologic Products Holdings, Inc. (CBPO)

 

CRISPR Therapeutics (CRSP) Investor Presentation - Slideshow

Aug. 13, 2019 2:26 PM ET|2 comments  | About: CRISPR Therapeutics AG (CRSP) 

CRISPR Therapeutics (CRSP) Investor Presentation - Slideshow Jan. 10, 2020 11:03 AM ET | About: CRISPR Therapeutics AG (CRSP)

EPS of $-0.26 beats by $0.09 Revenue of $17.55M (-18.06% Y/Y) beats by $3.96M

EPS of $-0.26 beats by $0.09 Revenue of $17.55M (-18.06% Y/Y) beats by $3.96M

EPS of $-0.26 beats by $0.09 Revenue of $17.55M (-18.06% Y/Y) beats by $3.96M

image758

 

Sangamo Therapeutics, Inc. 2019 Q2 - Results - Earnings Call Slides

Aug. 13, 2019 1:47 PM ET | About: Sangamo Therapeutics, Inc. (SGMO) 

EPS of $-0.25 beats by $0.04 Revenue of $35.99M (-20.52% Y/Y) beats by $6.37M

EPS of $-0.26 beats by $0.09 Revenue of $17.55M (-18.06% Y/Y) beats by $3.96M

EPS of $-0.26 beats by $0.09 Revenue of $17.55M (-18.06% Y/Y) beats by $3.96M

image759

 

Intrexon Corporation 2019 Q2 - Results - Earnings Call Slides

Aug. 9, 2019 6:29 PM ET | About: Intrexon Corporation (XON) 

earnings Call Slides Q2./HY 2019

EPS of $2.86 beats by $0.24 Revenue of $4.4B (15.36% Y/Y) beats by $175.57M

EPS of $2.86 beats by $0.24 Revenue of $4.4B (15.36% Y/Y) beats by $175.57M

EPS of $2.86 beats by $0.24 Revenue of $4.4B (15.36% Y/Y) beats by $175.57M

image760

 

Celgene Corporation 2019 Q2 - Results - Earnings Call Slides

Jul. 31, 2019 1:34 PM ET | About: Celgene Corporation (CELG) 

Amarin Corporation plc (AMRN)

EPS of $2.86 beats by $0.24 Revenue of $4.4B (15.36% Y/Y) beats by $175.57M

EPS of $2.86 beats by $0.24 Revenue of $4.4B (15.36% Y/Y) beats by $175.57M

 

Amarin Corporation plc 2019 Q2 - Results - Earnings Call Slides

Jul. 31, 2019 10:18 AM ET  | About: Amarin Corporation plc (AMRN) 

IT'S TIME TO TAKE ON PERSISTENT CV RISK WITH PROVEN THERAPIES

EPS of $-0.05 beats by $0.04 Revenue of $30.14M (32.46% Y/Y) beats by $1.3M

EPS of $2.86 beats by $0.24 Revenue of $4.4B (15.36% Y/Y) beats by $175.57M

EPS of $-0.05 beats by $0.04 Revenue of $30.14M (32.46% Y/Y) beats by $1.3M

image761

 

Veracyte, Inc. 2019 Q2 - Results - Earnings Call Slides

Jul. 31, 2019 3:06 PM ET | About: Veracyte, Inc. (VCYT) 

Abiomed, Inc. (ABMD)

Vertex Pharmaceuticals Incorporated (VRTX)

EPS of $-0.05 beats by $0.04 Revenue of $30.14M (32.46% Y/Y) beats by $1.3M

 

Abiomed, Inc. 2020 Q1 - Results - Earnings Call Slides

Aug. 1, 2019 10:03 AM ET | About: Abiomed, Inc. (ABMD) 

Abiomed JPM 2020 presentation

Becton, Dickinson and Company (BDX)

Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Incorporated (VRTX)

image762

 

Becton, Dickinson and Company 2019 Q3 - Results - Earnings Call Slides

Aug. 6, 2019 10:16 AM ET | About: Becton, Dickinson and Company (BDX) 

Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Incorporated (VRTX)

image763

 

Vertex Pharmaceuticals Incorporated 2019 Q2 - Results - Earnings Call Slides

Jul. 31, 2019 4:58 PM ET | About: Vertex Pharmaceuticals Incorporated (VRTX) 

©2018 MarketsandMarkets Research Private Ltd.

Biomarker Technologies Market

Biomarker Technologies Market

Biomarker Technologies Market

image764

 Biomarker Technologies Market by Profiling Technology (Chromatography, NGS, PCR, Mass Spectrometry, Immunoassay, Liquid Biopsy (ddPCR, DHPLC)), Research Area (Proteomics, Lipidomics), Application (Biomarker Validation, Biomarker Discovery) - Global Forecast to 2022

The global biomarker technologies market is expected to reach USD 74.51 Billion in 2022 from USD 42.88 Billion in 2016, at a CAGR of 9.7% during the forecast period. The base year considered for the study is 2016 and the forecast period is from 2017 to 2022.

Efficacy Testing Market

Biomarker Technologies Market

Biomarker Technologies Market

image765

 Efficacy Testing Market by Product and Service (Consumables, Services), Type (Antimicrobial Efficacy Testing, Disinfectant Efficacy Testing), Application (Pharmaceutical Manufacturing, Cosmetic & Personal Care Products) - Global Forecast to 2022

The efficacy testing market was valued at USD 304.2 Million in 2016 and is expected to reach USD 501.6 Million by 2022, at a CAGR of 8.7%. The base year for this study is 2016 and the forecast period is 2017–2022.

Oncology Nutrition Market

Biomarker Technologies Market

Oncology Information System Market

image766

 Oncology Nutrition Market by Cancer Type (Head & Neck, Stomach & Gastrointestinal, Liver, Pancreatic, Esophageal, Lung, Breast, Blood) - Global Forecast to 2023

The oncology nutrition market was valued at USD 1.34 Billion in 2017 and is expected to reach USD 2.21 Billion by 2023, at a CAGR of 8.7% during the forecast period. Factors such as the development of elemental formulas and product innovation in terms of non-GMO-based formulas present significant opportunities for the growth of oncology-based nutrition formulas.

Oncology Information System Market

Non Invasive Prenatal Testing (NIPT) Market

Oncology Information System Market

image767

 Oncology Information System Market by Software (Patient Information System & TPS), & Professional Service), Application (Medical, Radiation, & Surgical Oncology), End User (Hospital, Government Institution, & Research Center) - Global Forecasts to 2019

The market is expected to reach $2.6 billion by 2019 at a CAGR of 8.5% from 2014 to 2019.

Non Invasive Prenatal Testing (NIPT) Market

Non Invasive Prenatal Testing (NIPT) Market

Non Invasive Prenatal Testing (NIPT) Market

image768

 Non Invasive Prenatal Testing (NIPT) Market by Instruments (Ultrasound, NGS, PCR, Microarray), Consumables, Method (FCMB, cf-DNA), Application (Trisomy, Microdeletion, Genetics, Rh factor) & End User (Hospital, Diagnostic Labs) - Global Forecast to 2021

The non-invasive prenatal testing (NIPT) market is expected to reach USD 2.88 billion by 2021 from USD 1.35 billion in 2016 at a CAGR of 16.4% during the forecast period.

Bioinformatics Market

Non Invasive Prenatal Testing (NIPT) Market

Non Invasive Prenatal Testing (NIPT) Market

image769

 Bioinformatics Market by Product & Service (Knowledge Management Tools, Data Analysis Platforms (Structural & Functional), Services), Applications (Genomics, Proteomics & Metabolomics), & Sectors (Medical, Academics, Agriculture) - Global Forecast to 2023

The global bioinformatics market is projected to reach USD 13.50 billion in 2023 from USD 6.17 billion in 2017, at CAGR of 14.5%. The base year considered for the study is 2017, and the forecast for the market size is provided for the period between 2018 and 2023.

©2018 BlackRock, Inc. All Rights Reserved.

image770

Sep 25, 2018 By Bob Miller, Rick Rieder

 An exceptionally strong labor market and reasonably firm inflation
have the Fed monitoring the heat in the U.S. economy. 


image771

  September 2018 - 

BlackRock Investment Institute 

We see a growing disconnect between waning market attention to our top 10 geopolitical risks and the likelihood of some of them escalating. Our global BlackRock Geopolitical Risk Indicator (BGRI) has declined since our last update, suggesting the market’s attention to geopolitical risks overall has edged down. Yet the overall reading masks considerable dispersion, and we have raised the likelihood of three of our risks.Global trade tensions is our focus risk this month as U.S. trade disputes with major trading partners carry on. 

image772

 Sep 19, 2018 -  By Russ Koesterich 

 At $3.5 trillion per year, total healthcare spending (public and private) makes up roughly 20% of the U.S. economy. The nation’s 80 million baby boomers provide a stable source of ongoing revenue growth for healthcare companies throughout the value chain. Demographic tailwinds are widely expected to continue to propel this secular story in the United States. 

image773

 Sep 14, 2018 By Michael Fredericks

 In the United States, we continue to observe above-trend fundamental data, including strong corporate earnings, capital expenditures (business investment) and consumer sentiment. U.S. stocks notably outperformed international markets, with the S&P 500 Index rallying over 3% in August whereas European equities, for instance, were negative. We believe U.S. outperformance will likely persist in the near-term, underscoring our preference for more domestic-oriented assets. 

image774

 Oct 1, 2018

By BlackRock Investment Institute

 We see the steady global expansion rolling on, underpinned by above-trend U.S. growth. Yet the range of potential economic outcomes is widening. Gradual increases in U.S. rates are tightening financial conditions globally, and have contributed to bouts of volatility and sharply depreciating emerging market (EM) currencies. We also take a deep dive into the prospects for EMs after an unexpectedly drawn-out selloff. 

image775

 Oct 8, 2018 By Richard Turnill

 Global equities’ nearly decade-long bull run is stoking anxiety about its ability to power on. One concern: narrow breadth — a fragile state when a small group of stocks is contributing the lion’s share of market returns, buoying the broader index. We see today’s strong equity performance, especially in the U.S., as broad-based and driven by healthy fundamentals and solid earnings momentum. 

© 2018 Grand View Research, Inc. All rights reserved.

image776

 Posted On Sep, 05, 2018

Cancer Biomarkers Market: Increasing demand for rapid and specific cancer diagnosis

 

image777

Posted On Sep, 05, 2018 

Regenerative Medicine: Presence of strong product pipeline coupled with emerging applications in gene therapy projected to drive market


image778

 Increasing number of surgical procedures is driving the surgical instruments market 

Surgical Equipment/Instruments Market Analysis By Product (Sutures & Staplers, Handheld & Electrosurgical Devices), By Application (Neurosurgery, Plastic & Reconstructive Surgery, Obstetrics & Gynecology, Cardiovascular, Orthopedic), And Segment Forecasts, 2018 - 2025
image779

Posted On Sep, 05, 2018

 Biosimilars - A Pioneering Approach To Futuristic Treatments!


image780

   June 2018 

The global genomics market size is expected to reach USD 27.6 billion by 2025, according to a new report by Grand View Research, Inc., progressing at a CAGR of 9.7% during the forecast period.

image781

 Published Date: Sep, 2018

Metagenomics Market Size, Share & Trends Analysis Report By Product (Sequencing & Data Analytics), By Technology (Sequencing, Function), By Application (Environmental), And Segment Forecasts, 2018 - 2025

Some of the prominent players operating in this market are Illumina, Inc.; Promega Corporation; Novogene Corporation; Oxford Gene Technology, Inc.; Thermo Fisher Scientific, Inc.; TAKARA BIO INC.; Danaher; QIAGEN; and ELITechGroup. 


Copyright © 2018 seeking biotech alpha - All Rights Reserved. City Photos from  Pixabay

Powered by GoDaddy Website Builder

  • biotecMAX
  • BioHazard2020-3
  • BioHazard2020-2
  • BioHazard2020-1
  • BioHazard2020-0
  • 2021-1
  • 2020-6
  • 2020-5
  • 2020-4
  • 2020-3
  • 2020-2
  • 2020-1
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-9
  • 2019-8
  • 2019-7
  • 2019-4
  • 2019-3
  • biotecNOVA 2
  • BiotecNOVA 1
  • biotecHOPE
  • biotecHEART
  • portfolio
  • BiotecDATA
  • biotechVORTEX 2
  • biotechVORTEX 1
  • biotechSTORM/BiotecWARS
  • blogs
  • about

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

DeclineAccept